HOME > BUSINESS > Dr Reddy’s Labs launches osteoporosis drug in the US

Dr Reddy’s Labs launches osteoporosis drug in the US

Dr Reddy’s Laboratories Ltd said it launched raloxifene hydrochloride tablets –used to treat osteoporosis — in the US market.

Raloxifene hydrochloride tablets are a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets. A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use.

Raloxifene is used by women to prevent and treat bone loss (osteoporosis) after menopause. It slows down bone loss and helps to keep bones strong, making them less likely to break.

Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive breast cancer) after menopause.

The Evista brand and generic had US sales of approximately $265 million MAT for the most recent twelve months ending in September 2016 according to IMS Health.

Dr. Reddy’s Raloxifene tablets are available in 60 mg in bottle count sizes of 30, 100 and 1,000.

Evista is a registered trademark of Eli Lilly and Company.

The Food and Drug Administration (FDA or USFDA) is a federal agency of the United States Department of Health and Human Services, one of the United States federal executive departments. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and pharmaceutical drugs, vaccines, biopharmaceuticals etc.

Dr. Reddy’s Laboratories Ltd. is an India pharmaceutical company and offers products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Follow ULTRA.news
Zydus Cadila gets USFDA nod to launch generic version of billion-dollar drug Cialis eventually The United States Food and Drug Administration has given Zydus Cadila approval to launch a generic version of the billion-dollar erectile dysfunction drug Cialis when patents expire.The patents are expected to expire in September next year.Cialis and Viagra are the most ...
Glenmark Pharma to launch birth control pill in USA Glenmark Pharmaceuticals said it got the approval of the United States Food & Drug Administration to launch a generic version of birth control pill Loestrin from Allergan Pharmaceuticals International.The drug had annual sales of approximately $116.8 million.The drug Nor...
Strides Shasun gets USFDA nod to launch nausea drug Strides Shasun Limited said it received approval from the United States Food & Drug Administration (USFDA) to launch a generic version of Diamox Tablets.The primary use of the Acetazolamide is to reduce nausea and dizziness associated with altitude sickness, but the drug is ...
After Lupin, Ajantha Pharma too launches generic ADHD drug in US A month after Lupin got it, Ajanta Pharma too said it got the approval to launch a generic version of Concordia Pharmaceuticals Inc.’s ADHD drug Kapvay.Lupin had got the nod in October, and said the drug had sales of around $66 mln in the US.Ajantha Pharma also said it ha...
Cipla gets US approval for cancer drug, Glenmark for oral contraceptive Two Indian pharmaceutical companies, Cipla and Glenmark, said they received approval from the US Food and Drug Administration for new drugs.While Cipla got the nod for a drug used to treat a type of blood cancer, Glenmark was approved to sell an oral contraceptive.Cipla...
Strides Shasun says Eris deal to help reprioritize business, lower debt Pharma major Strides Shasun said it agreed to sell its India branded generics business to Eris LifeSciences Limited for Rs 500 cr in cash."This transaction is the outcome of the company's portfolio reprioritization, to focus more sharply on larger regulated markets," it said...
Zydus gets nod for anti-inflammation drug in the US Pharma major Zydus Cadila said it received final approval from the USFDA to market an anti-inflammatory injection Ethacrynate Sodium in the US.The drug is used to decrease the Swelling (edema) caused by various disease conditions such as liver disease, kidney disease, conges...
Cipla launches ashtha inhaler therapy in the US Pharma giant Cipla Ltd said it received final approval for launching a generic version of Astrazeneca’s Pulmicort inhalation suspension for pediatric asthma in the US.The product is available for shipping immediately, Cipla said.Pulmicort Respules and generic equivalent...
Suven Life Sciences gets patents in USA, India and Hong Kong Pharma company Suven Life Sciences Ltd said it received new patents in India, USA and Hong Kong for neurological drugs.The patents -- one each in Hong Kong and the US and a couple in India -- are valid through 2032, 2030 and 2034."The granted claims of the patents include...
Zydus Cadila has an excellent quarter in Q2, PAT up 33% Pharma giant Zydus Cadila reported excellent numbers for the September quarter, led by rising US revenue that lifted its margins and profits.For the second quarter ended September 30, 2017, Zydus Cadila reported Earnings before Interest, Depreciation and Tax (EBIDTA) of Rs. 8...
Zydus Cadila gets approval for cholesterol drug in Mexico Zydus Cadila said Mexico's drug regulator granted marketing approval to market its diabetes drug Lipaglyn in Mexico.The drug can be used to bring down cholesterol levels in patients even when conventional therapies like statins fail.“This approval of Saroglitazar in Mexi...
Lupin gets USFDA warning on Goa, Indore plans, to affect new approvals Pharma major Lupin said it a warning letter from the US Food and Drug Administration for its formulations manufacturing facilities in Goa and Indore on Monday."We are deeply disappointed to hove received this outcome. While there will be no disruption of existing product sup...
Biocon, Mylan apply again for EU approval for cancer drugs trastuzumab, pegfilgrastim Biocon said its partner Mylan has resubmitted the marketing application for two substances used to treat cancer -- trastuzumab and pegfilgrastim -- before European authorities after making changes to their production facilities.The drug applications before the European Medic...
Alembic Pharma buys US-based generics manufacturer Alembic Pharmaceuticals said it bought New Jersey-based generic drug developer Orit Laboratories LLC, which will bring seven approved generics and four applications with it.Orbit has "a team of eight highly experienced scientists," Alembic said, adding that the firm focuses ...
Lupin Q2 sales down 8%, PAT falls 31.3% Pharma major Lupin reported an 8% fall in Q2 revenue to Rs. 3,952 cr.Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) for the quarter fell by 13% to 927 cr.Net profit was also down by 31.3% at Rs 455 cr in in the September quarter. The profit was high...
CIA biggest beneficiary of Aadhaar, says Swamy; GST not behind slowdown BJP leader and libertarian politician Subramanian Swamy said he believes that the design of Aadhaar system exposes core data to 'American intelligence agencies' and expressed consternation that the government was continuing with the unique identification number scheme. Subraman...
Cipla gets USFDA nod to launch kidney drug in the US Pharma giant Cipla said it received final approval to market a generic version of Genzyme’s kidney drug Renvela Tablets in the US.Renvela Tablets had US sales of approximately $1.85 billion for the 12-month period ending August 2017, according to IMS Health.The approval...
Lupin gets USFDA approval for generic ADHD drug Pharma Major Lupin said it received final approval from the United States Food and Drug Administration (FDA) to market a generic version of Concordia Pharmaceuticals Inc.’s ADHD drug Kapvay.It had annual sales of approximately USD 66 million in the US.Clonidine Hydrochlo...
Suven Life Sciences gets patent for neuro drug Suven Life Sciences Ltd said it was granted a patent by New Zealand authorities for "a class of selective 5-HT4 compounds" that are being developed to treat neurodegenerative diseases.The compounds are being explored for use in cases of Alzheimer’s disease, Attention deficie...
USFDA returns Mylan-Biocon’s drug application for more data The U.S. Food and Drug Administration has sought more data before approving a chemotherapy compound submitted by Mylan and jointly developed by Biocon.The agency issued a 'complete response letter'. Such letters are issued when an FDA review an FDA review finds that an appli...